Healthequity (NASDAQ:HQY) issued its earnings results on Tuesday. The company reported $0.22 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.02, Morningstar.com reports. Healthequity had a net margin of 24.52% and a return on equity of 12.93%. The business had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.60 million. During the same quarter last year, the firm posted $0.17 EPS. The business’s revenue for the quarter was up 24.1% compared to the same quarter last year. Healthequity updated its FY 2019 guidance to $1.06-1.13 EPS and its FY19 guidance to $1.03-1.09 EPS.
Healthequity stock opened at $83.60 on Thursday. Healthequity has a 12-month low of $42.92 and a 12-month high of $101.58. The firm has a market cap of $5.19 billion, a P/E ratio of 154.81, a PEG ratio of 2.90 and a beta of 1.37.
In related news, VP Darcy G. Mott sold 4,000 shares of Healthequity stock in a transaction on Monday, October 22nd. The shares were sold at an average price of $87.01, for a total transaction of $348,040.00. Following the sale, the vice president now owns 92,500 shares of the company’s stock, valued at approximately $8,048,425. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 12,000 shares of company stock worth $1,027,400 in the last ninety days. 4.00% of the stock is currently owned by insiders.
A number of equities analysts have recently commented on HQY shares. Barrington Research reissued an “outperform” rating and issued a $100.00 target price on shares of Healthequity in a research note on Wednesday, September 5th. They noted that the move was a valuation call. Cantor Fitzgerald reissued a “hold” rating and issued a $82.00 target price on shares of Healthequity in a research note on Thursday. KeyCorp raised their target price on shares of Healthequity from $90.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, September 4th. ValuEngine downgraded shares of Healthequity from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, BidaskClub downgraded shares of Healthequity from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $93.23.
COPYRIGHT VIOLATION NOTICE: This story was published by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.wkrb13.com/2018/12/06/healthequity-hqy-posts-earnings-results-beats-estimates-by-0-02-eps.html.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Recommended Story: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.